PMID- 35145909
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and 
      Immunotherapeutic Targets.
PG  - 808396
LID - 10.3389/fonc.2021.808396 [doi]
LID - 808396
AB  - CD70 - a ligand protein of CD27 on lymphocytes - is expressed in a large spectrum 
      of malignancies. It is an attractive target for antibody-based therapy and 
      several clinical trials are currently being conducted. However, there is no 
      evidence regarding the expression of CD70 and its relationship with expression of 
      programmed death ligand-1 (PD-L1) and CD27+ tumor-infiltrating lymphocytes (TIL) 
      in formalin-fixed paraffin-embedded (FFPE) tissues of thymic tumors. FFPE tissues 
      of thymic squamous cell carcinoma (TSCC) (operative specimens, n = 31; biopsy 
      specimens, n = 11), thymoma (n = 60), thymic carcinoid (n = 3), and lung squamous 
      cell carcinoma (LSCC) (n = 30) were analyzed immunohistochemically. 
      Immunoreactivity for CD70 was semi-quantitatively scored according to the 
      proportion of positive tumor cells. Moreover, the densities of CD27-positive 
      intratumoral TIL (iTIL) and stromal TIL of TSCC were assessed and survival was 
      compared. Most TSCC cases (87%; 27/31) were CD70-positive. In contrast, all 
      thymoma and thymic carcinoid cases were CD70-negative. In LSCC cases, 
      CD70-positivity was significantly lower than TSCC cases (20%; 6/30). Biopsy and 
      resected specimens obtained from the same patients demonstrated a consistent 
      staining pattern (6/6 patients). The proportion of CD70-positive TSCC was 
      comparable with those of CD5 (87%) and CD117 (90%). Correlation between CD70 and 
      PD-L1 expression score was observed. There was no significant difference in 
      survival between the CD70-high and CD70-low expression groups. Meanwhile, 
      patients with CD27-positive iTIL-high tumors exhibited better survival than those 
      with iTIL-low tumors. This tendency was weaker in the CD70-high subset. CD70 
      immunohistochemistry is useful in diagnosing TSCC. CD70 may prevent anti-tumor 
      immunity via CD27. Immunotherapy targeting the CD70-CD27 axis may be a promising 
      option for the treatment of TSCC.
CI  - Copyright (c) 2022 Kashima, Hishima, Okuma, Horio, Ogawa, Hayashi, Horiguchi, 
      Motoi, Ushiku and Fukayama.
FAU - Kashima, Jumpei
AU  - Kashima J
AD  - Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, Tokyo, Japan.
AD  - Department of Pathology, Graduate School of Medicine, The University of Tokyo, 
      Tokyo, Japan.
FAU - Hishima, Tsunekazu
AU  - Hishima T
AD  - Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, Tokyo, Japan.
FAU - Okuma, Yusuke
AU  - Okuma Y
AD  - Department of Thoracic Oncology and Respiratory Medicine, National Cancer Center, 
      Tokyo, Japan.
FAU - Horio, Hirotoshi
AU  - Horio H
AD  - Department of Thoracic Surgery, Tokyo Metropolitan Cancer and Infectious diseases 
      Center Komagome Hospital, Tokyo, Japan.
FAU - Ogawa, Masumi
AU  - Ogawa M
AD  - Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, Tokyo, Japan.
FAU - Hayashi, Yukiko
AU  - Hayashi Y
AD  - Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, Tokyo, Japan.
FAU - Horiguchi, Shin-Ichiro
AU  - Horiguchi SI
AD  - Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, Tokyo, Japan.
FAU - Motoi, Toru
AU  - Motoi T
AD  - Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center 
      Komagome Hospital, Tokyo, Japan.
FAU - Ushiku, Tetsuo
AU  - Ushiku T
AD  - Department of Pathology, Graduate School of Medicine, The University of Tokyo, 
      Tokyo, Japan.
FAU - Fukayama, Masashi
AU  - Fukayama M
AD  - Department of Pathology, Graduate School of Medicine, The University of Tokyo, 
      Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220125
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8821901
OTO - NOTNLM
OT  - CD27
OT  - CD70
OT  - immunohistochemistry
OT  - thymic carcinoma
OT  - tumor-infiltrating lymphocyte
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/12 06:00
MHDA- 2022/02/12 06:01
PMCR- 2021/01/01
CRDT- 2022/02/11 05:41
PHST- 2021/11/03 00:00 [received]
PHST- 2021/12/29 00:00 [accepted]
PHST- 2022/02/11 05:41 [entrez]
PHST- 2022/02/12 06:00 [pubmed]
PHST- 2022/02/12 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.808396 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jan 25;11:808396. doi: 10.3389/fonc.2021.808396. eCollection 
      2021.